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common cause of ESRD.4 Patients with CKD, es-
pecially diabetic in etiology, suffer from a drasti-
cally increased risk of death due to cardiovascu-
lar causes.5,6 Simple albuminuria combined with 
a reduced filtration rate is a recognized cardio-
vascular risk factor.7 Early prevention and diag-
nosis of diabetic complications is the key to ef-
fective treatment.
On the other hand, in a selected group of 
patients with type 2 diabetes, DN was report-
ed to develop within 10 years after a diagno-
sis of diabetes in only 30.2% of the patients 
(24.9% with microalbuminuria and 5.3% with 
INTRODUCTION Primary and secondary kid-
ney diseases leading to end-stage renal disease 
(ESRD) are a serious health care problem around 
the world.1,2 Owing to recent changes in lifestyle, 
diabetic kidney disease (DKD; diabetic nephrop-
athy, DN) is now the major cause of deteriora-
tion of chronic kidney disease (CKD) leading to 
renal replacement therapy. By the end of 2012 in 
the United States, diabetic patients constituted 
39.3% of the patients with ESRD, while in 14.1% 
of the cases, it was caused by glomerulonephritis, 
and in 4.6%3—by autosomal dominant polycys-
tic kidney disease (ADPKD), also considered as a 
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ABSTRACT
INTRODUCTION Owing to the prevalence of type 2 diabetes, diabetic kidney disease (DKD) becomes the 
major cause of end-stage renal disease. The current markers of diabetic nephropathy are based on albu-
minuria and clinical signs of retinopathy. Sensitive and specific noninvasive diagnostic tools, unbiased by 
the presence of comorbidities, are needed, especially to detect the early stages of diabetic complications.
OBJECTIVES The aim of the study was to analyze changes in urinary protein excretion based on the 
stage of DKD using quantitative proteomics.
PATIENTS AND METHODS A total of 27 healthy controls were age- and sex-matched to 72 diabetes 
patients classified into 3 groups: no signs of retinopathy or nephropathy (n = 33), retinopathy but no 
microalbuminuria (n = 15), and diabetic nephropathy (DN) based on overt albuminuria or microalbuminuria 
with retinopathy (n = 24). To assess the intergroup differences, samples were partially pooled, tagged 
using 8-plex iTRAQ reagents, and the resulting peptide mixture was resolved by isoelectrofocusing. The 
obtained fractions were analyzed by liquid chromatography–tandem mass spectrometry (LC-MS/MS). Data 
were analyzed using the MASCOT software and dedicated in-house proteomic data analysis programs.
RESULTS The changes in the urine proteome following DKD progression involved some known protein 
markers of DN and several other proteins. Decreased levels of some proteins are presumably related 
to impaired secretory function of other organs affected by diabetes. In particular, a diminished excre-
tion of pancreatic amylase and deoxyribonuclease I suggested exocrine pancreatic insufficiency (EPI), 
coexisting with type 2 diabetes.
CONCLUSIONS A decrease in the urinary excretion of some pancreatic enzymes suggests EPI associated 
with diabetes. This hypothesis is yet to be verified; nevertheless, renal and extrarenal confounders must 
be considered when interpreting the results of quantitative urinary proteomics.
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included in this group. Group D+R (type 2 diabe-
tes with retinopathy) included samples from pa-
tients with diabetes and ophthalmologic signs 
of DR but no markers of nephropathy with re-
gards to microalbuminuria, overt albuminuria, 
or decreased glomerular filtration rate (GFR). 
This group was considered as having “early dia-
betic complications” with respect to the lack of 
biochemical markers of impaired renal function. 
Group DN (overt DN) included samples from pa-
tients with diabetes and overt DN with albumin-
uria, indicating the presence of advanced diabetic 
damage to the nephrons. It included patients with 
albuminuria, characterized by a wide range of the 
albuminuria level, namely with macroalbuminuria 
defined as a urinary albumin-to-creatinine ratio 
(UACR) over 34 mg/mmol or microalbuminuria 
(3.4–34 mg/mmol), but in the latter case, with 
parallel signs of DR, in accordance with the KDO-
QI criteria.10 Owing to the small size of the study 
group, patients with DR were pooled into 1 group 
without further assignment to specific subcate-
gories (proliferative, nonproliferative, or diabet-
ic macular edema).16 Patients with DR were clas-
sified into the third or fourth subgroup, but the 
principal classifier was based on the verification 
of albuminuria.
Pooled sample studies A total of 27 patients were 
assigned to group C (control), 33 to group D (dia-
betes with no complications), 15 to group D+R (di-
abetes + retinopathy) and 24 to group DN (overt 
DN). The characteristics of the groups, including 
age, sex, biochemical parameters, diabetes du-
ration, concomitant diseases, and administered 
drugs, are provided in TABLE 1.
Pooling samples, iTRAQ study design, qualitative 
MS/MS, and quantitative iTRAQ analysis The sam-
ple preparation protocol, pooling samples, iTRAQ 
study design, mass spectrometry settings, mass 
spectrometry qualitative data processing, and 
quantitative iTRAQ analysis were described in 
detail in Supplementary material online.
Quantitative analysis of proteins using label-free 
method To verify the experiment with pooled 
samples labeled by iTRAQ, we conducted a la-
bel-free quantitation of a selected set of proteins 
for individual (nonpooled) samples analyzed in 
a single liquid chromatography–mass spectrom-
etry (LC-MS) run. Each LC-MS run was preced-
ed by a blank run to ensure the lack of carry-over 
of material from the previous analyses. The label-
free quantitative analysis and statistical analysis 
of quantitative MS results were described in de-
tail in Supplementary material online.
Statistical analysis of amylase activity and urinary al-
bumin-to-creatinine ratio The Kruskal–Wallis test 
was used to compare amylase activities and UACR 
since no normal distribution was confirmed in the 
Shapiro–Wilk test.
macroalbuminuria).8 Progression has been linked 
to the genetic background,9 and a special focus 
on these cases is of great clinical importance. Al-
though the Kidney Disease Outcomes Quality Ini-
tiative (KDOQI) and Kidney Disease: Improving 
Global Outcomes guidelines recommend assessing 
microalbuminuria for DKD screening, they also 
underscore the insufficient sensitivity of this test. 
The intraindividual variability in urinary albumin 
excretion depends on numerous factors, includ-
ing coexisting diseases, exertion, body mass, and 
temperature, making this type of screening po-
tentially unreliable. Although diabetic retinopa-
thy (DR) in the presence of microalbuminuria ac-
cording to the KDOQI guidelines on DKD is con-
sidered an equivalent marker of DN (overt albu-
minuria),10 the correlation between DR and DKD 
may be biased. A discordance has been reported, 
with a fraction of patients not exhibiting coex-
isting retinopathy and nephropathy, as verified 
by kidney biopsy.11-12 However, these findings are 
consistent with the observed differences in the 
pathogenesis of retinopathy and nephropathy. 
The urine proteome provides an opportunity to 
search for a potential diagnostic tool for kidney 
disease and DN, though its application is current-
ly hampered by numerous limitations, which still 
remain to be solved.13-15
In the present work, we performed a quan-
titative urinary proteome analysis of patients 
with type 2 diabetes using the iTRAQ technolo-
gy. This approach, coupled with peptide prefrac-
tionation by isoelectrofocusing, has not been used 
previously for urinary proteomics in DN. Ow-
ing to variability in clinical characteristics, we 
distinguished between 4 categories. Changes in 
the urine proteome were correlated with various 
stages of diabetes complications, particularly the 
stage including DR without albuminuria and re-
nal dysfunction.
PATIENTS AND METHODS Patient selection and 
urine samples The project was approved by 
the local ethics committee (approval number, 
KB/643/08). Patients enrolled in the study were 
selected from inpatients hospitalized at Mied-
zyleski Specialist Hospital in Warsaw. Informed 
consent was obtained before collecting urine sam-
ples. The study was performed in accordance with 
the Declaration of Helsinki. Patients selection 
protocol, inclusion and exclusion criteria, and 
urine sample preparation were described in de-
tail in Supplementary material online.
Sample classification We distinguished 4 study 
subgroups based on the clinical characteristics of 
diabetic patients. Group C (control) was the con-
trol sample set collected from healthy individuals 
without diabetes or any of the exclusion criteria. 
Group D (type 2 diabetes with no nephropathy) 
comprised samples from patients with diabetes 
but no biochemical markers of DKD or ophthal-
mologic signs of DR. Patients with a diagnosis of 
diabetes established during hospitalization, were 
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the second component, indicating the presence 
of a specific group of features/proteins that cor-
relate with disease progression to the D+R stage. 
In contrast, the overt DN group was clearly differ-
entiated from the other 3 along the first compo-
nent, and along the second component DN was 
much closer to D than to D+R. This observation 
indicates that a different group of proteins follows 
the progression of disease from C through D to 
D+R than the progression from D to DN (TABLE 2). 
RESULTS Our data showed marked differences 
between the groups. The principal component 
analysis showed a separation of all pseudosam-
ples in the plane of the 2 components. The close 
position of technical replicates (samples marked 
A and B) confirmed a very good technical quality 
of our results (FIGURE 1). Interestingly, the progres-
sion from control (C) to type 2 diabetes without 
nephropathy (D) and type 2 diabetes with reti-
nopathy (D+R) was marked by a clear shift along 
TABLE 1 Characteristics of study groups
Characteristics Group C (healthy 
controls without 
diabetes)
Group D (diabetes and no 
diabetic kidney disease: 
no albuminuria and no 
diabetic retinopathy)
Group D+R (diabetes and 
diabetic retinopathy with 
no albuminuria)
Group DN (diabetes with 
overt diabetic nephropathy 
[albuminuria] or 
microalbuminuria with 
retinopathy)
No. of patientsa (men/
women)
27 (15/12) 33 (18/15) 15 (9/6) 24 (15/9)
age, y 48 ±14 (27–71) 60 ±12 (39–86) 72 ±11 (48–85) 68 ±8 (51–81)
urinary albumin-to-
creatinine ratio, mg/
mmol/dm3
0.77 ±0.9 (0.14–5) 1.21 ±1.08 (0–5) 1.40 ±0.9 (0.05–3.33) 57 ±94b
(0.5–396)
eGFR, ml/min/1.73m2 93.5 ±24.9 96.3 ±30.4 87.3 ±48.8 49.9 ±24.3
HbA1c, % – 8.24 ±2.73 (assayed in 
61% of subjects)
8.06 ±2.01 (assayed in 
73%)
7.27 ±1.97 (assayed in 
71%)
diabetic retinopathy 0% 0% and 15% hypertensive 
angiopathy
100% 42% and 16% hypertensive 
angiopathy, 42% not 
available
diabetes duration – 1 month – 10 years 5–25 years <1 year – 21 years
diabetic retinopathy 0% 0% and 15% hypertensive 
angiopathy
100% 42% and 16% hypertensive 
angiopathy, 42% not 
available
diabetes duration – 1 month – 10 years 5–25 years <1 year – 21 years
common coexisting diseases
hypertension 33% 88% 80% 96%
stable congestive heart 
failure
0% 15% 27% 42%
benign prostate 
hypertrophy
4% 3% 20% 13%
patients taking drugs known to influence albuminuria/proteinuria
ACEI/ARB 15% 77% 80% 96%
β-blockers 15% 59% 53% 79%
diuretics 4% 41% 67% 71%
statins 19% 65% 73% 54%
hypoglycemic drugs
insulin 0% 35% 67% 58%
biguanids 0% 74% 47% 46%
sulphonylurea derivatives 0% 18% 20% 13%
other commonly used drugs
acetylsalicylic acid 7% 47% 40% 46%
calcium channel blockers 11% 41% 40% 58%
α-blockers 7% 3% 20% 4%
Data are presented as number of patients, percentage of patients, or mean ± standard deviation (range).
a During the MS experiment, each group was divided into 3 equal subgroups to triplicate MS assays on pooled samples. 
b Data are skewed due to the broad range of albuminuria in the samples. Standard deviation has no use as it is not a normal distribution in this case.
Abbreviations: ACEI, angiotensin-converting enzyme inhibitors; ARB, angiotensin receptor blockers; eGFR, estimated glomerular filtration rate 
(calculated using the Modification of Diet in Renal Disease formula); HbA1c, hemoglobin A1c; MS, mass spectrometry
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in diabetes compared with diabetes without albu-
minuria (ie, α-1B-glycoprotein, β-1B-glycoprotein 
[hemopexin], zinc-α-2-glycoprotein, and α-2-HS-
glycoprotein), zinc-α-2-glycoprotein was differen-
tiating in our study. In group D+R, the protein 
was slightly upregulated with a ratio of 1.21 com-
pared with control. A ratio of 1.02 was obtained 
for DN, but the q-value was not significant. Also 
α-1-acid-glycoprotein was found upregulated in 
D+R (TABLE 2). Another extracellular glycoprotein 
from the serpin family, α1-antitrypsin, was ele-
vated in DN, consistently with previous results 
for overt nephropathy.18 Interestingly, for group 
D+R, we found reduced α1-antitrypsin levels. In 
agreement with a previous study,18 we observed 
a decreased excretion of apolipoprotein A-I in 
groups D and D+R. On the other hand, the ex-
cretion of prostaglandin-H2 D-isomerase, an ear-
ly marker of DKD, was upregulated in D+R (1.24) 
as anticipated, and not significantly decreased 
in DN.19 The same trend was observed for osteo-
pontin upregulated in groups D (1.32) and D+R 
(1.39). Albumin, the most abundant protein, was 
increased in DN (1.56), but almost unchanged in 
groups D (1.1) and D+R (1.05). We observed a sig-
nificant pattern of increased urinary immuno-
globulin chain secretion (Ig λ-3 chain C region, 
Ig κ chain C region, Ig κ chain V-I region BAN, Ig 
λ-7 chain C region, immunoglobulin λ-like poly-
peptide 5) in group D+R, 2 of them in group D 
Some of these proteins have already been identi-
fied as altered in diabetic complications, where-
as some have not been mentioned previously to 
be associated with the disease.
To test the pooling experiment results using an 
alternative analytical approach, we carried out a 
label-free analysis of individual samples assigned 
to 4 groups: C, 12 samples; D, 15 samples; D+R, 14 
samples; and DN, 10 samples. To obtain quanti-
tative information, 0.5-µg protein of each of the 
51 samples was subjected to the LC-MS analysis 
(C, n = 12; D, n = 15; D+R, n = 14; DN, n = 10). Of 
the differentiating proteins identified in iTRAQ, 
only 4 were quantitated in the label-free analy-
sis owing to smaller protein coverage expected in 
the case of a single LC-MS run. FIGURE 2 shows the 
results of the label-free analysis for serum albu-
min, pancreatic α-amylase, proepidermal growth 
factor, and deoxyribonuclease I. Box-plots con-
firm the results of the analysis of pooled samples, 
showing the same trends of change and verifying 
the pooling experiment.
Validation of previously reported markers We 
found, among others, numerous proteins previ-
ously described as the markers of DN.17 The re-
sults are presented in TABLE 2, and q-values indi-
cate statistical significance. From a group of glyco-
proteins with a known pathophysiological role in 
diabetes and previously found to be upregulated 
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FIGURE 1 Principal 
component analysis; 3 
pooled biological 
replicates of control (C), 
diabetes (D), diabetes + 
retinopathy (D+R), and 
diabetic nephropathy 
(DN) samples were 
analyzed based on 520 
proteins
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protein was detected but its level was not signif-
icantly altered. The exception was cathepsin D, 
a protein excreted from proximal tubules, the 
levels of which were increased almost 2-fold in 
group D+R. The cytoplasmic actin level was re-
duced in groups D and D+R. We did not detect 
collagen type IV (α-2 or α-1 chain), the main ex-
tracellular matrix protein with high urinary excre-
tion recognized as an early marker of DN and as-
sociated with the deterioration of renal function 
in type 2 diabetic patients, even without overt 
proteinuria.21,22 In the case of a complex matrix, 
global LC-MS analyses can detect only the most 
(Ig λ-3 chain C regions and Ig κ chain C region), 
but none in DN. Some urinary immunoglobulin 
fragments were previously reported as increased 
in diabetes and DN.20 Interestingly, the level of 
low affinity immunoglobulin gamma Fc region 
receptor III-A was decreased in D+R.
Several proteins indicative of tubular damage, 
including cystatin C, neutrophil gelatinase-asso-
ciated lipocalin, α-N-acetylglucosaminidase, fatty 
acid-binding protein, and β2-microglubulin, were 
detected, but changes in their expression could 
not be confirmed because of insignificant corre-
sponding q-values. Similarly, vitamin D-binding 
TABLE 2 Proteins previously reported as related to diabetic nephropathy with altered levels in pairwise comparisons
Protein Protein ID Number of 
peptides
Not complicated 
diabetes vs control 
(D vs C)
Diabetes with 
retinopathy vs 
control (D+R vs C)
Overt nephropathy vs 
control (DN vs C)
q-value ratio q-value ratio q-value ratio
serum albumin P02768 191 8×10–5 1.1 0.67 1.05 1.6×10–4 1.56
collagen α-2(IV) chain P08572 NA
collagen α-1(I) chain P02452 18 1 1.09 0.73 0.94 5.9×10–4 0.41
α-2-HS-glycoprotein P02765 14 0.96 0.93 0.99 0.96 0.84 0.79
β-1B-glycoprotein (hemopexin) P02790 20 0.40 0.94 0.92 1.09 0.68 0.93
α-1B-glycoprotein P04217 29 0.98 1.06 0.98 0.97 0.45 0.89
α-1-acid glycoprotein P02763 29 0.55 1.15 6×10–5 1.46 0.87 1.25
α-1-antitrypsin P01009 69 0.92 0.96 6×10–3 0.82 0.01 1.57
zinc-α-2-glycoprotein P25311 39 1 1.08 0.02 1.21 0.26 1.02
prostaglandin-H2 D-isomerase P41222 55 0.03 1.09 1.6×10–3 1.24 0.47 0.82
basement membrane-specific heparan 
sulfate proteoglycan core protein
P98160 49 0.02 0.85 0.03 0.88 4.6×10–2 0.59
complement factor B P00751 4 0.92 0.93 0.41 1.85 0.91 0.96
cathepsin D P07339 28 0.21 1.13 6×10–5 1.61 0.99 1.12
nephrin O60500 NA
osteopontin P10451 35 8×10–5 1.32 6 × 10–5 1.39 0.79 0.73
vitamin D-binding protein P02774 10 0.42 0.87 0.74 1.18 0.43 0.83
cystatin-C P01034 5 0.29 1.2 0.98 1.06 0.38 1.29
neutrophil gelatinase-associated lipocalin P80188 9 0.24 0.74 0.61 0.67 0.66 1.23
α-N-acetylglucosaminidase P54802 30 0.78 0.99 0.97 0.76 0.91 1.04
fatty acid-binding protein P07148 4 0.96 1.08 0.76 1.23 0.50 1.18
β-2-microglobulin P61769 3 0.68 0.83 0.76 0.76 0.28 0.55
Ig λ-3 chain C regions P0CG06 30 0.03 1.37 0.03 1.53 0.98 1.18
Ig κ chain C region P01834 35 0.03 1.28 0.01 1.4 0.96 0.91
Ig λ-7 chain C region A0M8Q6 20 0.06 1.37 0.03 1.67 0.97 1.17
Ig κ chain V-I region BAN P04430 3 0.23 1.68 0.04 2.66 0.83 0.8
immunoglobulin λ-like polypeptide 5 B9A064 31 0.08 1.29 9×10–3 1.58 0.90 1.18
low-affinity immunoglobulin γ Fc region 
receptor III-A
P08637 6 0.96 1.13 0.03 0.68 0.26 0.53
actin cytoplasmic 1 P60709 19 0.04 0.84 0.01 0.82 0.49 0.65
apolipoprotein A-I P02647 12 0.03 0.77 1.7×10–3 0.55 0.99 1.04
q-values <0.05 are shaded. The other values are given for comparison only, as their regulation status (ratio) did not reach the threshold of statistical 
validity.
Abbreviations: NA – not assayed
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proteins (prostaglandin-H2 D-isomerase, Ig λ-3 
chain C regions, Ig κ chain C region) were simi-
larly upregulated in group D, but none of them 
were found to be differentiating in group DN.
Proteins with decreased excretion in all analyzed 
groups Seven proteins were decreased in all 3 an-
alyzed groups, including pancreatic α-amylase and 
deoxyribonuclease I related to the exocrine pan-
creatic system, α-amylase 2B, salivary α-amylase 
1, proepidermal growth factor, mannan-binding 
lectin serine protease 2, and perlecan (TABLE 4). 
To verify the observed trend in the amylase ra-
tio, the total urinary amylase activity was deter-
mined for 99 individual samples comprising all 
studied groups in parallel with urinary amylase-
to-creatinine ratio (FIGURE 3). In the multiple Krus-
kal–Wallis comparison, we observed a significant 
difference between groups C and D (P = 0.045) 
and C and DN (P = 0.007). For the UACR, a sig-
nificant difference was observed only in the case 
of group C vs group DN (P = 0.0076), but a de-
creasing trend was visible in group C vs group D 
(P = 0.146).
DISCUSSION In the present study, the list of 
changes in the urine proteome following the 
progression of DN includes some known pro-
tein markers of the disease, some specific mark-
ers for certain stages of the disease, and several 
proteins related to exocrine pancreatic function. 
abundant proteins, and a targeted analysis us-
ing a more sensitive multiple reaction monitor-
ing  mode should be applied for the detection of 
a predefined set of proteins. Our study focused 
on the identification of a new protein panel. How-
ever, we detected a decreased level of the colla-
gen α-1(I) chain belonging to fibril-forming col-
lagen as differentiating (ratio, 0.41) in the case of 
the DN group. It is consistent with data report-
ed elsewhere that the urinary excretion of many 
collagen fragments detected by mass spectrom-
etry is generally decreased in CKD, in contrast to 
proteins derived from serum.18 This list includes 
fibril forming I, II, III, V, and XVII collagen types, 
as well as the type comprising subendothelium 
and basement membranes (VIII). The collagen-
derived peptides were also observed to be rela-
tively decreased in studies on CKD273 classifier 
for prognosis of CKD progression.22 On the other 
hand, α-2 (IV) chain, an early marker of DKD, was 
described to be increased in immunoassays,23 but 
was not reported in the published list.18 Further-
more, the basement membrane-specific heparan 
sulfate proteoglycan core protein (perlecan) was 
detected and decreased in all analyzed groups.24
Proteins with elevated excretion in group D+R but 
not DN The panel of 14 proteins specifically up-
regulated in group D+R deserves attention be-
cause it is potentially indicative of early diabetic 
complications (TABLE 3). Interestingly, only 3 other 
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of drugs, especially with the more advanced stag-
es of diabetic complications. These confounders 
affect the urinary proteome. The drugs known to 
reduce proteinuria can be selective against only 
some proteins because they are excreted with dif-
ferent filtration and reabsorption rates.25
Proteins consistently decreased in all progression stages 
We also found proteins with consistent trends of 
decreased excretion following the analyzed stag-
es: proepidermal growth factor, mannan-bind-
ing lectin serine protease 2, and basement mem-
brane-specific heparan sulfate proteoglycan core 
protein (perlecan). Mannan-binding lectin serine 
protease 2 is associated with the lectin pathway 
of complement activation and also plays a role in 
IgA nephropathy.26,27 Perlecan is an integral com-
ponent of basement membranes and provides a 
fixed negative charge involved in charge-selective 
ultrafiltration. In DN, the expression of glycos-
aminoglycan side chains of perlecan in the glo-
merular basement membrane is reduced in pro-
portion to the degree of proteinuria.24 To the best 
of our knowledge, the urinary level of this pro-
tein has not been studied so far.
The proepidermal growth factor physiological-
ly cleaved into epidermal growth factor (EGF) is 
a single-pass type I membrane protein expressed 
in the kidney, salivary gland, cerebrum, and pros-
tate. EGF stimulates the growth of various epider-
mal and epithelial tissues and some fibroblasts. In 
addition, EGF acts as a magnesiotropic hormone 
stimulating magnesium reabsorption in the renal 
This finding may indicate exocrine pancreatic in-
sufficiency (EPI) overlapping the subsequent stag-
es of DKD. According to our hypothesis and liter-
ature data, EPI may be causally related to diabe-
tes. Although the proteins secreted by the exo-
crine pancreas and excreted into urine should be 
increased due to protein leakage in DN, we ob-
served a reverse phenomenon. The observed de-
crease in amylase excretion suggests the presence 
of other processes accompanying renal clearance 
of proteins in DKD because diabetes affects oth-
er organs and their protein secretion.
Proteins with excretion specifically elevated in group 
D+R As mentioned above, protein markers in 
diabetes patients with retinopathy but without 
biochemical markers of renal impairment may 
have a crucial diagnostic meaning for early pre-
vention. The proteins listed in TABLE 3, especially 
those upregulated in D+R, deserve interest as po-
tential markers differentiating the stages of di-
abetic complications other than overt renal im-
pairment. The excretion level of prostaglandin-H2 
D-isomerase in group D+R (ratio 1.24) meets our 
expectations consistent with the results describ-
ing this protein as an early marker of DN.19 How-
ever, a further decrease of this protein in group 
DN could not be confirmed due to an insufficient 
q-value for the observed ratio.
Several factors may obscure the expected ten-
dency in protein excretion levels. As shown in 
TABLE 1, patients were burdened with numerous co-
existing diseases and a complicated combination 
TABLE 3 Proteins with elevated excretion in diabetes with retinopathy vs control groups
Protein Protein ID Number of 
peptides
Not complicated 
diabetes vs control  
(D vs C)
Diabetes with 
retinopathy vs control 
(D+R vs C)
Overt nephropathy vs 
control (DN vs C)
q-value ratio q-value ratio q-value ratio
prostaglandin-H2 D-isomerase P41222 55 0.03 1.09 1.6×10–3 1.24 0.47 0.82
acid ceramidase Q13510 24 0.07 1.28 6×10–5 1.78 1 0.96
α-1-acid glycoprotein 1 P02763 29 0.55 1.15 6×10–5 1.46 0.87 1.25
α-1-acid glycoprotein 2 P19652 18 0.30 1.09 0.03 1.41 0.98 1.17
zinc-α-2-glycoprotein P25311 39 1 1.08 0.03 1.21 1 1.02
leucine-rich α-2-glycoprotein P02750 25 0.29 1.14 9.4×10–3 1.34 0.98 0.93
lysosomal protective protein
(cathepsin A)
P10619 12 0.18 1.45 5.4×10–3 2.43 0.96 1.03
protein AMBP (α-1-microglubulin/
bikunin)
P02760 65 0.23 1.08 7.1×10–3 1.17 0.74 0.77
β-galactosidase P16278 22 0.81 1.09 0.02 1.51 0.73 0.89
cathepsin B P07858 11 0.18 1.38 0.02 1.54 0.77 0.77
cathepsin D P07339 28 0.21 1.13 6×10–5 1.61 0.99 1.12
annexin A2 P07355 7 0.58 1.14 0.03 1.99 0.67 0.68
Ig λ-7 chain C region A0M8Q6 20 0.06 1.37 0.03 1.67 0.98 1.17
Ig κ chain V-I region BAN P04430 3 0.23 1.68 0.04 2.66 0.83 0.8
Ig λ-3 chain C regions P0CG06 30 0.03 1.37 0.03 1.53 0.98 1.18
Ig κ chain C region P01834 35 0.03 1.28 0.01 1.4 0.96 0.91
immunoglobulin λ-like polypeptide 5 B9A064 31 0.08 1.29 9.1×10–3 1.58 0.90 1.18
q-values <0.05 are shaded.
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few studies directly interested in possible cor-
relations between diabetic neuropathy and exo-
crine pancreatic dysfunction are available” and 
further research is needed.31 The hypothesis that 
the trophic action of insulin directed at acinar 
cells producing enzymes in the pancreas under 
conditions of insufficient insulin secretion affect 
exocrine function was discarded on the basis of 
the lack of changes in the pancreatic glands of 
most type 1 diabetes patients. Also, the fact that 
pancreatic changes observed in type 2 diabetes 
cannot be explained by the local lack of insulin, 
especially in early stages, does not support that 
hypothesis.31 The causal relationship between 
diabetes and EPI is not well explored clinically, 
though recent work has pointed to an increased 
risk of overall and acute pancreatitis associated 
with diabetes.35 Instead, a reverse cause–effect 
relationship between pancreatic β-cells dysfunc-
tion and chronic pancreatitis, progressing to di-
abetes, is more often considered.36,37
An alternative explanation for the obtained 
results could be the decreased glomerular filtra-
tion of amylases as well as increased tubular re-
absorption. These two mechanisms play a role in 
renal clearance of pancreatic and salivary amy-
lases but with more active reabsorption of sali-
vary isozyme.38 In general, the urinary secretion 
of amylases is considered in terms of the amy-
lase creatinine clearance ratio (ACCR), which in-
cludes amylase and creatinine concentrations in 
urine and serum (ACCR = urine amylase/serum 
amylase × serum creatinine/urine creatinine × 
100).39 Previous studies point to an association 
between increased ACCR and renal insufficien-
cy. However, in terms of urinary but not serum 
amylase concentration, the simple ratio of uri-
nary amylase to urinary creatinine was not higher 
in patients with chronic renal insufficiency rela-
tive to healthy controls.39 The literature data are 
distal convoluted tubule. Defects in EGF are the 
cause of hypomagnesemia type 4, known as re-
nal hypomagnesemia with normocalciuria.28 The 
significance of decreased excretion of this precur-
sor protein is not clear.
Hypothesis of exocrine pancreatic insufficiency co-
existing with diabetes We observed decreasing 
trends in the levels of 3 amylase isozymes; pan-
creatic α-amylase, α-amylase 2B (novel type),29 
and salivary α-amylase 1. Compared with con-
trols, these proteins exhibited decreased excretion 
in all 3 groups, unlike urinary albumin excretion, 
which was increased in DN. We also observed a 
diminished excretion of deoxyribonuclease I, se-
creted by the exocrine pancreatic glands. We did 
not detect lipases, phospholipases, or elastase-1. 
The lack of elastase-1 was expected knowing its 
excretion in an unchanged form in the feces.30
The possible diabetes-related pathophysiologi-
cal explanation of the decreased excretion of pan-
creatic enzymes observed in our study was dis-
cussed in detail elsewhere.31 That study found a 
correlation between exocrine pancreatic function 
and decreased secretion of amylases and lipases 
into the blood after pancreozymin-secretin stim-
ulation in diabetic patients, as well as decreased 
fecal elastase-1. Pancreatic histology in autop-
sy studies has revealed substantial changes in 
the exocrine glands of diabetic patients, includ-
ing chronic inflammation, approximately twice 
more frequent in diabetics than nondiabetics.32 
Autopsy also often shows pancreatic atrophy.33 A 
smaller pancreas has also been shown in imaging 
studies of living patients with diabetes.34 The au-
thors discussed whether dysfunction in the exo-
crine pancreas associated with diabetes may be 
related to diabetic neuropathy, affecting the au-
tonomic nervous system, which regulates exo-
crine function. They emphasized that “only very 
TABLE 4 Downregulated urinary proteins associated with exocrine pancreatic function, salivary glands, and some other proteins whose level was 
decreased consistently in all analyzed groups; all results obtained with achieved statistical threshold
Protein Protein ID Number of 
peptides
Not complicated diabetes 
vs control  
(D vs C)
Diabetes with 
retinopathy vs control 
(D+R vs C)
Overt nephropathy vs 
control (DN vs C)
q-value ratio q-value ratio q-value ratio
proteins associated with pancreatic exocrine function
pancreatic α-amylase P04746 46 8×10–5 0.81 6×10–5 0.7 6.1x10–4 0.49
deoxyribonuclease-1 P24855 25 0.01 0.8 2.6×10–3 0.71 8.2×10–3 0.44
salivary isozyme of amylase
α-amylase 1 P04745 40 3.1×10–3 0.86 3×10–4 0.74 1.4×10–3 0.5
other proteins with decreased excretion
α-amylase 2Ba P19961 41 6.4×10–4 0.84 6×10–5 0.69 3×10–3 0.5
proepidermal growth factor P01133 32 8×10–5 0.69 6×10–5 0.6 1.6×10–4 0.46
mannan-binding lectin serine 
protease 2
O00187 11 0.02 0.75 0.03 0.64 4.8×10–2 0.37
basement membrane-specific 
heparan sulfate proteoglycan 
core protein (perlecan)
P98160 49 0.02 0.85 0.03 0.88 0.04 0.59
a novel type amylase, expressed in tumorous tissue, probably liver-specific
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Although the results obtained from MS quanti-
tation are difficult to translate into classical terms 
of clearance, they show absolute underrepresen-
tation of amylase compared to total excreted pro-
tein, arguing for the role of EPI. We also found a 
trend for decreasing amylase activity as diabetes 
progresses to DN. We found the alternative re-
nal cause of decreased urinary amylase to be less 
not conclusive regarding the ACCR in CKD. An in-
creased ACCR was reported for both pancreatic 
and salivary isozymes in patients with noncom-
pensated renal failure.40 However, an elevated 
ACCR in CKD may be caused by increased serum 
creatinine rather than increased urinary amylase, 
which may be evident if creatinine clearance falls 
below 50 ml/min.41
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total observed effect of decreased amylase levels 
may reflect the synergy of several different fac-
tors. Pancreatic insufficiency is rather unlikely in 
ADPKD. One of the kidney diseases associated 
with pancreatic dysfunction is von Hippel–Lindau 
disease, which can mimick ADPKD and confuse 
the diagnosis.45 However, although pancreatic 
cysts occur in 70% of the patients with von Hip-
pel–Lindau disease and rarely cause exocrine and 
endocrine insufficiency, pancreatic cysts are found 
only in 9% of ADPKD patients. In light of the de-
creased urinary amylase excretion in ADPKD, the 
tendency of decreased pancreatic protein excre-
tion in DN reveals a complex effect resulting from 
EPI and, possibly, from impaired renal function.
Study limitations It is obvious that pooling 
samples flattens biological diversity, which was 
the reason for verifying crucial protein con-
tents in individual samples. Although the sin-
gle reaction / multiple reaction monitoring tech-
niques would be the method of choice, the label- 
-free quantitation was applied in the frame of 
project budget for some proteins.
Summary DKD disturbs urinary protein excre-
tion on various levels, including the urinary tract 
and prerenal factors. Although the glomerular and 
tubular parts of the nephron play a central role 
in the mechanism preserving protein balance, 
the prerenal contribution to the contents of pro-
tein preload is crucial when diabetes affects other 
body organs and may influence the urinary pro-
teome. Using MS/iTRAQ, we have demonstrated 
decreased excretion of pancreatic amylases and 
deoxyribonuclease I, which may originate from 
EPI related to diabetes. The pathomorpholog-
ical proof of this condition was described else-
where. However, overlapping CKD as an alterna-
tive cause of the observed phenomenon should 
be confirmed, and the parallel decrease in urinary 
salivary isozyme elucidated.
Supplementary material online Supplementary 
material online is available with the online ver-
sion of the paper at www.pamw.pl.
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probable. The increased urinary protein leakage is 
expected in glomerular damage unless compen-
sating reabsorption in proximal tubules increas-
es to counteract protein loss, which is rather un-
likely. The tubular contribution to amylase clear-
ance was described previously for a case of acute 
pancreatitis. Its impairment due to renal insuf-
ficiency resulted in reduced amylase reabsorp-
tion and accounted for the elevated amylase ex-
cretion in regard to pancreatic and salivary iso-
zymes.42 The decreased level of deoxyribonucle-
ase I observed in our study supports coexisting 
pancreatic dysfunction.
The reason for the decreased level of salivary 
amylase isozyme is less clear. A common mech-
anism that impairs the exocrine function of the 
pancreas in diabetes may consequently affect oth-
er organs including salivary glands. On the other 
hand, if the reason is on the kidney filtration–re-
absorption side, the excretion trends would be dif-
ferent for pancreatic and salivary isozymes. Some 
studies have reported preferable reabsorption of 
salivary isozymes in proximal and distal tubules.43
Urinary excretion of differentiating proteins in other 
diseases Our laboratory has recently described 
the uroproteome characteristics of ADPKD44 and 
IgA nephropathy (Bakun et al.; in preparation) 
using the standardized protocol. Differentiating 
proteins in these conditions can be compared to 
the results of the present study. Interestingly, 
similar relative deficits in pancreatic α-amylase 
(ratio, 0.7) and salivary α-amylase 1 (0.47) were 
found in ADPKD samples compared with con-
trols. Such decreases in amylases were not ob-
served in IgA nephropathy. Also, similar to DN, 
decreased levels of proepidermal growth factor 
and perlecan were found in both ADPKD and IgA 
nephropathy. However, the direction of change 
in other proteins was different in diabetes and 
other conditions. This reversed tendency was ob-
served for apolipoprotein A-I (3.89 in ADPKD vs 
0.55 in D+R) and α-1-antitrypsin (1.64 and 2.47 
for ADPKD and IgA nephropathy, respectively, 
vs 0.82 in D+R). The β2-microglobulin was also 
strongly upregulated in ADPKD (3.69), but not 
in DN. Serum albumin excretion was more in-
creased in IgA nephropathy (3.56) and ADPKD 
(1.69) compared with the 3 diabetic groups in 
the present study (1.1, 1.05, and 1.56 for D, D+R, 
and DN, respectively). Thus, the urine proteome 
revealed changes that are common for different 
conditions, as well as some changes specific for 
a given disease. In the context of a discussion of 
amylase clearance in CKD, it is questionable to as-
sociate the decreased urinary amylase level with 
the decreased GFR observed in diabetes or in AD-
PKD. Reabsorption failure in renal tubules, con-
comitant with impaired filtration, can be specu-
lated to increase amylase excretion.
The decreased excretion of pancreatic rele-
vant proteins, observed in ADPKD, obviously 
does not exclude hypothesis of EPI as a cause of 
their diminished excretion in type 2 diabetes. The 
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SŁOWA KLUCZOWE
amylaza, cukrzycowa 
choroba nerek, 
nefropatia cukrzy-
cowa, proteomika 
moczu, zewnątrz-
wydzielnicza 
niewydolność trzustki
STRESZCZENIE
WPROWADZENIE Ze względu na rozpowszechnienie cukrzycy typu 2, cukrzycowa choroba nerek (diabetic 
kidney disease – DKD) staje się główną przyczyną schyłkowej niewydolności nerek. Wykorzystywane 
obecnie markery nefropatii cukrzycowej opierają się na albuminurii i klinicznych cechach retinopatii. 
Potrzebne są – zwłaszcza do wykrywania wczesnych stadiów powikłań – czułe i swoiste nieinwazyjne 
narzędzia diagnostyczne, niewrażliwe na choroby współistniejące.
CELE Celem pracy była analiza zmian wydalania białek z moczem w zależności od stadium DKD za po-
mocą technik proteomiki ilościowej.
PACJENCI I METODY 27 zdrowych ochotników w grupie kontrolnej dopasowano pod względem wieku 
i płci do 72 pacjentów z cukrzycą, przydzielonych do trzech grup: bez cech retinopatii i nefropatii (n = 
33); z retinopatią, ale bez albuminurii (n = 15); z nefropatią cukrzycową (diabetic neuropathy – DN), po-
twierdzoną na podstawie jawnej albuminurii lub mikroalbuminurii z retinopatią (n = 24). W celu określenia 
różnic międzygrupowych próbki zostały częściowo spulowane, oznakowane za pomocą odczynnika iTRAQ 
w wersji 8-kanałowej, a mieszanina wynikowych peptydów rozdzielona za pomocą izoelektroogniskowania. 
Otrzymane frakcje analizowano za pomocą metody chromatografii cieczowej sprzężonej z tandemową 
spektrometrią mas (LC-MS/MS). Zebrane dane analizowano za pomocą programu MASCOT i własnych 
programów do analizy danych proteomicznych.
WYNIKI Zmiany w proteomie moczu towarzyszących postępowi DKD dotyczyły wielu znanych markerów 
DN oraz innych białek. Obniżony poziom wydalania kilku z nich wiąże się prawdopodobnie z upośledzoną 
funkcją wydzielniczą innych narządów dotkniętych cukrzycą. Zwłaszcza zmniejszone wydalanie amylazy 
trzustkowej i deoksyrybonukleazy I sugeruje zewnątrzwydzielniczą niewydolność trzustki (exocrine pan-
creatic insufficiency – EPI), nakładającą się na cukrzycę typu 2.
WNIOSKI Spadek wydalania z moczem kilku enzymów związanych z trzustką sugeruje EPI na tle cukrzycy. 
Hipoteza ta wymaga dalszej weryfikacji, niemniej podczas interpretacji wyników ilościowej proteomiki 
moczu należy brać pod uwagę czynniki nerkowe i pozanerkowe.
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Full description of patients and methods 
 
Patient selection and urine samples 
The project was approved by the local ethics committee (approval number KB/643/08). 
Patients enrolled in the study were selected from inpatients hospitalized at Miedzyleski 
Specialist Hospital in Warsaw. Informed consent was obtained before collecting urine 
samples. The study was performed in accordance with the Declaration of Helsinki. The 
control samples were collected from inpatients admitted for routine diagnosis or hospitalized 
for reasons not affecting the urinary tract. A few healthy controls were also selected from 
outpatients. Blood samples for routine examination of the health status were collected 
according to a standard protocol required for hospitalization. Candidates were selected on the 
basis of their medical records, physical examination, and laboratory tests, including red and 
white cell counts, C-reactive protein, creatinine and urea levels, blood glucose concentration, 
albumin, and total protein concentration. A general urine examination, including albuminuria 
and urine creatinine for the urinary albumin-to-creatinine ratio (UACR), was also carried out. 
Transaminase assays and hepatitis B and C tests were performed on admission to the hospital, 
and patients with abnormalities were excluded from the study. All of the basic assays were 
performed using the hospital’s automated analyzer (Beckman Couler/Synchron System) and 
standard protocols. The creatinine concentration was determined using the classic Jaffe 
method [1]; total amylase activity, using AMY7 reagent [2]; and albuminuria, using the 
turbidimetric method in the Synchron LX system.  
 Inclusion and exclusion criteria  
Patients with diabetes are naturally burdened with several other diseases, with diabetes as a 
general cause of these complications on the background of metabolic imbalance and vascular 
damage. Thus, conditions concomitant to diabetes and diabetic kidney disease (DKD), 
including hypertension, dyslipidemia, congestive heart failure (stable New York Heart 
Association class up to class II), stable coronary artery disease, and atrial flutter/fibrillation, 
were not excluded. Candidates with conditions that influence the urine proteome, including 
urinary tract infections, suspected glomerulopathies other than those of diabetic origin, 
abnormalities revealed by liver markers, immunological and hematological clonal diseases, 
cancer, pneumonia, and patients in a bad general condition were excluded. 
 
Sample classification 
We distinguished 4 groups based on the clinical characteristics of diabetic patients. Group C 
(control) was the control sample set collected from healthy individuals without diabetes or 
any of the exclusion criteria. Group D (type 2 diabetes with no nephropathy) comprised 
samples from patients with diabetes but no biochemical markers of DKD or ophthalmologic 
signs of diabetic retinopathy (DR). Patients with a diagnosis of diabetes established during 
hospitalization, were included in this group. Group D+R (type 2 diabetes with retinopathy) 
included samples from patients with diabetes and ophthalmologic signs of DR but no markers 
of nephropathy with regards to microalbuminuria, overt albuminuria, or decreased glomerular 
filtration rate (GFR). This group was considered as having “early diabetic complications” 
with respect to the lack of biochemical markers of impaired renal function. The diabetic 
nephropathy (DN) group (overt DN) included samples from patients with diabetes and overt 
DN with mandatory albuminuria, indicating the presence of advanced diabetic damage to the 
nephrons. Here, we assigned patients with albuminuria, characterized by a wide range of the 
albuminuria level, namely with macroalbuminuria defined as a UACR over 34 mg/mmol or 
microalbuminuria (3.4–34 mg/mmol), but in the latter case the latter case, with parallel signs 
of DR, in accordance with the Kidney Disease Outcomes Quality Initiative (KDOQI) criteria 
[3]. Simultaneously, elevated creatinine and decreased GFR were markers of chronic kidney 
disease, rather than factors affecting classification, according to the definition of DKD 
independent of GFR, which can be even elevated in the hyperfiltration stage. The assessment 
of albuminuria in controls after 3 to 6 months was not technically possible, though it is 
recommended by KDOQI for the diagnosis of DKD. In the fourth group, roughly half of the 
patients (42%) had signs of DR and 16%––hypertensive angiopathy. In 42% of the subjects, 
an ophthalmologic examination was not available, but they had overt macroalbuminuria. 
Owing to the small size of the study group, patients with DR were pooled into 1 group 
without further assignment to specific subcategories (proliferative, nonproliferative, or 
diabetic macular edema) [4]. Patients with DR were classified into the third or fourth 
subgroup, but the principal classifier was based on the verification of albuminuria.  
 
Pooled sample studies 
Twenty-seven patients were assigned to group C (control); 33, to group D (diabetes with no 
complications); 15, to group D+R (diabetes + retinopathy); and 24, to group DN (overt DN). 
The exact characteristics of the groups, including age, sex, biochemical parameters, diabetes 
duration, concomitant diseases, and administrated drugs, are provided in Table 1 of the main 
text. 
 
Sample preparation 
All included patients provided clean-catch urine samples (~80 ml) at random time (11 AM – 2 
PM). The time interval between sample collection and preceding urination was at least 2 
hours, but no more than 4 hours. Urine samples were stored at room temperature for less than 
1 hour and processed using a modified standard protocol [5,6]. Briefly, 4 ml of 1 M HEPES 
(pH 7.2) buffer was added to 46 ml of urine in a Falcon tube to a final volume of 50 ml, 
vortexed for 2 minutes, and centrifuged at 3000 rcf for 10 minutes to remove cellular debris. 
The supernatant was filtered through 0.45 μm Roth syringe filters, then thoroughly mixed, 
aliquoted in 1-ml portions, and frozen at –80°C for further analysis. Frozen samples were 
transported in dry ice and thawed only once for further preparation. 
 
Sample filtration 
Cutoff membrane filters (10 kDa, Amicon Ultra-0.5, Millipore) were washed twice with 
MilliQ water prior to use. Urine was centrifuged through the membrane at 14000×g (15 min). 
Next, 500 µl of water was added to the retentate and centrifugation was repeated. To recover 
the concentrated and desalted sample, the filter was placed upside down in a clean 
microcentrifuge tube and centrifuged for 2 minutes at 1000×g. The protein concentration was 
measured using the Bradford method and aliquots stored at –80°C. 
 
Pooling samples and iTRAQ study design 
Samples from each study group were divided into 3 pools: n = 9 each in the control subgroups 
(C I–III), n = 11 each in the diabetes subgroups (D I–III), n = 5 in diabetes with rethinopathy 
group subgroups (D+R I–III), and n = 8 in diabetic nephropathy subgroups (DN I–III). From 
each sample within the subgroup, aliquots corresponding to 100 µg of protein were pooled 
into pseudosamples. Two aliquots of each pseudosample were obtained, representing 2 
technical replicates (marked A and B), resulting in a set of 24 pooled pseudosamples to be 
compared after iTRAQ labeling (the set of the 3 pools within each of the 4 study groups were 
evaluated twice). Because 8-plex iTRAQ was used, 2 technical replicates of each group were 
compared in one liquid chromatography–tandem mass spectrometry (LC-MS/MS) 
experiment. To analyze 24 samples, we conducted a set of 3 independent LC-MS/MS 
experiments.  
iTRAQ labeling 
Reagents for iTRAQ labeling were provided in the Applied Biosystems iTRAQ kit. Before 
labeling, protein aliquots were evaporated to dryness in a speedvac, dissolved in 20 μl 
dissolution buffer with 0.1%  sodium dodecyl sulphate, reduced with tris(2-
carboxyethyl)phosphine, cysteine-blocked with methyl methanethiosulfonate, and digested 
overnight with trypsin (Promega). Each group of samples was differentially labeled with 1 of 
the 8 iTRAQ tags (113 and 114 for C samples, 115; 116 for D, 117; 118 for D+R, 119; 121 for 
DN) for 2 hours according to the manufacturer’s protocol. The reaction was quenched by 
100 µl H2O. 
For each of the 3 LC-MS/MS experiments, 2 C, 2 D, 2 D+R, and 2 DN iTRAQ-labeled 
samples were combined and 340 µl buffer added (8M urea, 0.2% IPG buffer pH 3–11 NL [GE 
Healthcare, Fairfield CT, USA] 0.002% bromophenol blue in 50 mM Tris-HCl, pH 8.0). The 
solution was applied to an 18-cm IPG strip with 3–11 NL pH gradients (GE Healthcare) for 
isoelectrophocusing: 340 µl of sample/strip, corresponding to 400 µg of protein. The 
immobilized pH gradient (IPG) strip was rehydrated overnight in an IPG box). The next day, 
the strips underwent IEF using an Ettan IPGphor 3 electrophoresis system. Two 
electrophoresis steps were used. The first step consisted of a 5-hour prerun at 500 V. During 
this step, the conductivity decreased and salts and other highly conductive compounds moved 
towards the electrode (anode). In the second step, a long gradient focusing program was used: 
1 h at 500 V, 9 h at 1000 V, and 30 h at 8000 V with a final current of 5 µA. 
After IEF, the strip was removed from the tray, and the overlay oil blotted with a paper tissue. 
The strip was wrapped in parafilm and stored at –80°C. For sectioning, the tissue was placed 
on a tray, cooled with dry ice, cut into 7-mm sections, and transferred into individual 1.5-ml 
siliconized Eppendorf tubes. In total, 18-cm-long gel strips were sliced into 26 sections. 
Peptides were extracted from gel sections by 2 cycles: addition of 60 µl 0.1% trifluoroacetic 
acid and 2% acetonitrile, and vortexing the tubes for 40 min at room temperature. Aliquots 
with extracted peptides were stored at –80°C for LC-MS/MS analysis. 
 
Mass spectrometry: LC-MS/MS settings 
The peptide mixture (20µl) was applied to a nanoACQUITY UPLC Trapping Column 
(Waters) using water containing 0.1% formic acid as the mobile phase and then transferred to 
a nanoACQUITY UPLC BEH C18 Column (Waters, 75 µm/250-mm) using an acetonitrile 
gradient (3–33% over 150 min) in the presence of 0.1% formic acid at a flow rate of 250 
nl/min. The column outlet was directly coupled to the ion source of the LTQ-Orbitrap Velos 
mass spectrometer (Thermo Scientific, USA) working in the regime of data-dependent MS to 
MS/MS switch. Higher-energy collisional dissociation (HCD) fragmentation was used. Other 
Orbitrap parameters were as follows: one MS scan followed by max. 5 MS/MS scans, 
capillary voltage 1.5 kV, data acquired in positive polarity mode. 
 
Mass spectrometry: qualitative MS/MS data processing 
The acquired MS/MS data were preprocessed with Mascot Distiller (version 2.3.2.0, Matrix 
Science). A database search using the MASCOT search engine was carried out in a 3-step 
procedure described elsewhere [7] to calculate MS and MS/MS measurement errors and to 
recalibrate the data for the repeated MASCOT search. The initial search parameters were set 
as follows: enzyme, semitrypsin; fixed modification, cysteine modification by MMTS and 
iTRAQ labeling of the N-terminus of peptides and lysine side chains; variable modifications, 
oxidation (M); max missed cleavages, 1. The Swiss-Prot database was searched with the 
taxonomy restricted to Homo sapiens (20249 sequences). For the repeated search, the 
recalibrated data from all gel sections were merged into 1 input file and, using MASCOT, 
searched against the Swiss-Prot database supplemented with a decoy database to obtain a 
statistical assessment of the identification of each peptide by a joined target/decoy database 
search strategy [8]. This procedure provided q-value estimates for each peptide spectrum 
match (PSM) in the dataset. All PSMs with q-values exceeding 0.01 were removed from 
further analysis. A protein was regarded as confidently identified if at least 2 of its peptides 
were found. Proteins identified by a subset of peptides from another protein were excluded 
from analysis. Proteins that exactly matched the same set of peptides were clustered into one 
group/cluster. MS/MS spectra of peptides meeting the above acceptance criteria were 
subjected to quantitative analysis to obtain a list of proteins differentially populated between a 
set of groups (Differential Protein List). 
 
Mass measurement error correction 
The maximum mass deviation (MMD) for precursor and fragment ions was established in a 
procedure involving 2 database searches separated by a mass recalibration step. Data from 
each LC-MS/MS run was searched in the first pass with permissive MMD settings (precursor 
ions, ±40 ppm; fragment ions, ±0.8 Da). The resulting Mascot DAT files were next imported 
to an in-house Java tool (DATViewer, http://proteom.ibb.waw.pl/datviewer/index.html), 
which implements a procedure for systematic mass errors elimination and high accuracy 
MMD estimation. Only PSMs with a score value exceeding the smaller of the Mascot identity 
and homology thresholds were used for the mass accuracy assessment. For each LC-MS/MS 
run, the mass correction was performed by fitting a smooth LOESS curve to the scatterplot of 
the observed mass errors vs precursor ion masses. The obtained normalization function was 
then used for the entire set of precursor ions. A separate calibration function was also 
calculated for fragmentation spectra on the basis of the masses of singly charged y-series ions. 
The new MMD values were estimated as 3-fold the standard deviation of the mass errors after 
recalibration. Finally, the mass-corrected spectra were exported as Mascot Generic File 
format files and resubmitted to the database search engine to obtain final peptide and protein 
identifications. 
 
Identification estimation q-value  
For the statistical assessment of peptide assignments, the fragmentation spectra were matched 
against a joined target/decoy database [8]. The target part of the database containing true 
protein sequences was concatenated with a decoy part composed of reversed versions of these 
sequences. All peptide PSMs, from the forward and reverse database, were sorted according 
to their score modified by subtracting the smaller of the Mascot identity and homology 
thresholds. The number of false positive identifications associated with a specific position P 
in the sorted list was estimated by doubling the number PSMs from the decoy part of the 
database at positions not greater than P. The position-related false discovery rate (FDR) was 
calculated by dividing the estimated number of false positives by the total number of PSMs at 
preceding positions. To address the fact that FDR itself is not a function of the underlying 
score (ie, FDR can decrease with increasing position in the sorted list), the position-related 
FDRs were next converted to q-values, as described by Kall et al.[9]. The presented analysis 
was performed using a proprietary software tool implemented in the Java programming 
language (MScan, http://proteom.ibb.waw.pl/mscan/index.html). 
 
iTRAQ quantitative analysis 
For protein quantitation, only unique peptides (peptides belonging to only 1 protein/cluster) 
were included. In the first step, iTRAQ reporter ion peaks were detected in the preprocessed 
MS/MS spectra. Next, the intensities were corrected for isotope impurity using the 
information provided by the reagent manufacturer. For each spectrum, the geometric means of 
2 reporter ion intensities belonging to 1 study group were calculated separately. The ratio of 
those mean values was reported as the peptide ratio. If more than 1 spectrum was obtained for 
a peptide in a single LC-MS/MS experiment, the median peptide ratio for all spectra was 
used. Prior to calculating the protein ratio, peptide ratios were median-normalized to remove 
systematic bias. Protein ratios were calculated as the median ratio of their peptide ratios. The 
significance of a single protein ratio was assessed by Diffprot [10]. In this program, the 
statistical validity of the expression status of the protein, represented by its calculated protein 
ratio, is based solely on a statistical analysis of the MS/MS datasets from a given experiment 
without assumptions about the character of the distribution of peptide ratios in a dataset (its 
normality). The probability of obtaining a given protein ratio by random selection from the 
dataset was tested by calculating protein ratios for a large number of permuted decoy datasets 
in which the peptide-protein assignment was scrambled. Calculated p-values were adjusted 
for multiple testing using a procedure controlling for the FDR. The significance threshold for 
iTRAQ quantitative analysis was set at q-value of less than 0.05.  
 
Label-free quantitative analysis 
LC-MS settings 
To verify the experiment with pooled samples labeled by iTRAQ, we conducted a label-free 
quantitation of a select set of proteins for individual (nonpooled) samples analyzed in a single 
LC-MS run. Each LC-MS run was preceded by a blank run to ensure a lack of carry-over of 
material from the previous analyses. 
First, qualitative analyses (peptide and protein identification) were performed on pooled urine 
samples in a data-dependent MS-to-MS/MS acquisition mode. Up to 5 MS/MS processes 
were allowed for each MS scan. To increase the number of peptide identifications, 3 LC-
MS/MS runs were performed per pooled sample, each covering 1 of 3 ranges of m/z values: 
300–600, 500–900, and 800–2000. This approach was found to substantially improve the 
coverage of protein identification. 
Quantitative analyses of individual samples were carried out in separate survey scans of LC-
MS runs with an m/z measurement range of 300 to 2000 using the same acetonitrile gradient 
as in the qualitative LC-MS/MS runs. The data-dependent MS-to-MS/MS switch was 
disabled, and the spectrometer resolution was set to 15000. 
 
Qualitative MS data processing and database search 
Qualitative MS data processing and a database search were conducted as described for 
iTRAQ-labeled samples, but with the following differences in search parameters: fixed 
modification, carbamidomethylation (C); variable modifications, oxidation (M). Only PSMs 
with q-values of 0.01 or lower were regarded as confidently identified. Proteins identified by 
a subset of peptides from another protein were excluded from analysis, and proteins matching 
the same set of peptides were clustered into single groups. 
 
Quantitative MS data processing 
The list of peptide identifications from the LC-MS/MS runs was overlaid onto 2-dimensional 
maps generated from the LC-MS profile data for individual samples. A more detailed 
description of the feature extraction is provided elsewhere [11]. Briefly, the list of identified 
peptides was used to tag the corresponding peptide-related ion spectra on the basis of m/z 
value, the deviation from the predicted elution time, and the match between theoretical and 
observed isotopic envelopes. The relative abundance of each peptide ion was determined as 
the height of a 2-dimensional fit with the most prominent peak of the tagged isotopic 
envelope. 
After the feature extraction, a filter was applied to the dataset to remove peptide ions with 
missing quantitative values in more than 20% of the samples. To avoid the removal of strictly 
differential peptides (ie, detected or missing in only one of the studied groups of samples), the 
χ2 test was used to assess significant inequalities in the distribution of the missing values in 
the sample groups. Next, a modified k-nearest neighbors procedure was used to input the 
remaining missing values. The applied modifications included the usage of variable size 
neighborhoods and correlation-based metric instead of the Euclidean distance. 
To minimize the effects of nonbiological sources of variation, log-transformed peptide 
abundance was normalized by fitting a robust locally weighted regression smoother (LOESS) 
between the individual samples and a median pseudosample. The parameters of the fit were 
established using a set of features exhibiting low variance in the unnormalized data and then 
applied to the whole data set. Finally, the normalized peptide-level data was rounded up to 
relative protein abundance. The procedure involved rescaling the abundance of peptides that 
originate from the same protein to a common level, followed by computing their median 
value. 
Statistical analysis of quantitative MS results from label-free analysis 
To select differentially expressed proteins, a nonparametric analysis of variance-based 
resampling test was used. The resulting P values were corrected for multiple hypothesis 
testing using a 2-step Benjamini–Hochberg procedure that controls for FDR [12]. Relative 
protein abundances with adjusted P values (≤0.01) and fold change values of 2 and higher 
were considered significantly changed in at least one of the studied groups. All statistical 
analyses were performed using a proprietary software running in the MATLAB environment 
(MathWorks; MStat, http://proteom.ibb.waw.pl/). 
 
 
Statistical analysis of amylase activity and UACR 
The Kruskal–Wallis test was used to compare amylase activities and UACR since no normal 
distribution was proven in the Shapiro–Wilk test. 
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